161 related articles for article (PubMed ID: 16126334)
1. Radiolabelled somatostatin analog therapy in prostate cancer: current status and future directions.
Liu Y
Cancer Lett; 2006 Jul; 239(1):21-6. PubMed ID: 16126334
[TBL] [Abstract][Full Text] [Related]
2. Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors.
Krenning EP; Teunissen JJ; Valkema R; deHerder WW; deJong M; Kwekkeboom DJ
J Endocrinol Invest; 2005; 28(11 Suppl International):146-50. PubMed ID: 16625865
[TBL] [Abstract][Full Text] [Related]
3. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.
Anthony LB; Woltering EA; Espenan GD; Cronin MD; Maloney TJ; McCarthy KE
Semin Nucl Med; 2002 Apr; 32(2):123-32. PubMed ID: 11965607
[TBL] [Abstract][Full Text] [Related]
4. In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives.
McCarthy KE; Woltering EA; Anthony LB
Q J Nucl Med; 2000 Mar; 44(1):88-95. PubMed ID: 10932605
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.
Breeman WA; de Jong M; Kwekkeboom DJ; Valkema R; Bakker WH; Kooij PP; Visser TJ; Krenning EP
Eur J Nucl Med; 2001 Sep; 28(9):1421-9. PubMed ID: 11585303
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine tumors. Peptide receptor radionuclide therapy.
Forrer F; Valkema R; Kwekkeboom DJ; de Jong M; Krenning EP
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):111-29. PubMed ID: 17382268
[TBL] [Abstract][Full Text] [Related]
7. Potential indications for somatostatin analogues: immune system and limphoproliferative disorders.
Ferone D; Resmini E; Boschetti M; Arvigo M; Albanese V; Ceresola E; Pivonello R; Albertelli M; Bianchi F; Giusti M; Minuto F
J Endocrinol Invest; 2005; 28(11 Suppl International):111-7. PubMed ID: 16625859
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy.
Zamora PO; Bender H; Gulhke S; Marek MJ; Knapp FF; Rhodes BA; Biersack HJ
Anticancer Res; 1997; 17(3B):1803-8. PubMed ID: 9179237
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
Janson ET
J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and therapeutic applications of radiolabeled somatostatin analogs: current status in an oncology center.
Podoloff DA
Curr Pharm Des; 2002; 8(20):1809-14. PubMed ID: 12171532
[TBL] [Abstract][Full Text] [Related]
11. New treatment approaches for prostate cancer based on peptide analogues.
Stangelberger A; Schally AV; Djavan B
Eur Urol; 2008 May; 53(5):890-900. PubMed ID: 18201818
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
Miederer M; Henriksen G; Alke A; Mossbrugger I; Quintanilla-Martinez L; Senekowitsch-Schmidtke R; Essler M
Clin Cancer Res; 2008 Jun; 14(11):3555-61. PubMed ID: 18519789
[TBL] [Abstract][Full Text] [Related]
13. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
14. Candidates for peptide receptor radiotherapy today and in the future.
Reubi JC; Mäcke HR; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():67S-75S. PubMed ID: 15653654
[TBL] [Abstract][Full Text] [Related]
15. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer.
Okarvi SM
Cancer Treat Rev; 2008 Feb; 34(1):13-26. PubMed ID: 17870245
[TBL] [Abstract][Full Text] [Related]
16. [Somatostatin receptor endoradiotherapy of neuroendocrine tumors: experience in Hungarian patients].
Reismann P; Kender Z; Dabasi G; Sréter L; Rácz K; Igaz P
Orv Hetil; 2011 Mar; 152(10):392-7. PubMed ID: 21354955
[TBL] [Abstract][Full Text] [Related]
17. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
18. The role of somatostatin analogs in the management of prostate cancer.
Sinisi AA; Rossi V; Prezioso D; Notaro A; Bellastella G; Panza N; Bellastella A; Pasquali D
J Endocrinol Invest; 2003; 26(8 Suppl):120-4. PubMed ID: 15233227
[No Abstract] [Full Text] [Related]
19. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors.
Kvols LK; Woltering EA
Anticancer Drugs; 2006 Jul; 17(6):601-8. PubMed ID: 16917205
[TBL] [Abstract][Full Text] [Related]
20. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9.
Sun LC; Luo J; Mackey LV; Fuselier JA; Coy DH
Cancer Lett; 2007 Feb; 246(1-2):157-66. PubMed ID: 16644105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
